1 | adverse | 52,978 |
2 | untoward | 226 |
3 | 'adverse | 12 |
4 | thrombovascular | 10 |
5 | arteriothrombotic | 8 |
6 | complications/adverse | 6 |
7 | cpp-l | 6 |
8 | cv/cb | 6 |
9 | skeleton-related | 5 |
10 | non-aids/death | 4 |
11 | placebo.adverse | 4 |
12 | thrombotic/vascular | 4 |
13 | time-to-cv | 4 |
14 | toxic/adverse | 4 |
15 | administration-related | 3 |
16 | hostility-related | 3 |
17 | intrasedation | 3 |
18 | iop-related | 3 |
19 | nonsignal | 3 |
20 | volume-related | 3 |
21 | 'remedy | 2 |
22 | anaphylactoid-like | 2 |
23 | anti-alf | 2 |
24 | athero-thrombotic | 2 |
25 | bleeding/adverse | 2 |
26 | cerebrovascular/cardiovascular | 2 |
27 | drug-adverse | 2 |
28 | embolic/thrombotic | 2 |
29 | emotion-filled | 2 |
30 | function-modifying | 2 |
31 | group.adverse | 2 |
32 | groups.adverse | 2 |
33 | ild-like | 2 |
34 | incisional-complication | 2 |
35 | local-site | 2 |
36 | meta-analysis.adverse | 2 |
37 | osteoactive | 2 |
38 | participants.adverse | 2 |
39 | pre-gliotic | 2 |
40 | renal/hypertension | 2 |
41 | safety/adverse | 2 |
42 | stress/life | 2 |
43 | stroke/thromboembolic | 2 |
44 | toxicities/adverse | 2 |
45 | toxicity/adverse | 2 |
46 | treatment.adverse | 2 |
47 | years.secondary | 2 |
48 | ''adverse | 1 |
49 | 11/1223 | 1 |
50 | 13,308 | 1 |
51 | 16,679 | 1 |
52 | 3/4-related | 1 |
53 | 4,986 | 1 |
54 | 5544 | 1 |
55 | 6.9+/-1.7 | 1 |
56 | 6414 | 1 |
57 | action-contingent | 1 |
58 | adverge | 1 |
59 | advers | 1 |
60 | adverses | 1 |
61 | aps-related | 1 |
62 | asa-related | 1 |
63 | asynchronic | 1 |
64 | axl-dependent | 1 |
65 | bcr-mediated | 1 |
66 | behavioural-pharmacological | 1 |
67 | both.adverse | 1 |
68 | bph-defining | 1 |
69 | bradyarrhythmic | 1 |
70 | calamitous | 1 |
71 | calculation.cardiovascular | 1 |
72 | cardiothrombotic | 1 |
73 | cardiovasculars | 1 |
74 | cardioâ-vascular | 1 |
75 | cerebralvascular | 1 |
76 | cerebroischemic | 1 |
77 | cerebrovasular | 1 |
78 | ceverbrovascular | 1 |
79 | chd.chd | 1 |
80 | chnpp | 1 |
81 | cholinergically-mediated | 1 |
82 | chronic-inflammatory | 1 |
83 | cisplatin-dependent | 1 |
84 | clinician-documented | 1 |
85 | co-benefit | 1 |
86 | competition-like | 1 |
87 | cononary | 1 |
88 | context/meaning | 1 |
89 | cospeciation | 1 |
90 | cross-setting | 1 |
91 | cyc=154 | 1 |
92 | deferiprone.adverse | 1 |
93 | deleterius | 1 |
94 | desferrioxamine.adverse | 1 |
95 | disclosable | 1 |
96 | disulfiram-alcohol | 1 |
97 | domino-type | 1 |
98 | dopaminergic/stimulant | 1 |
99 | effect.adverse | 1 |
100 | effects.adverse | 1 |
101 | efficacy-versus-adverse | 1 |
102 | epac-based | 1 |
103 | errors/adverse | 1 |
104 | esophageal-related | 1 |
105 | et-related | 1 |
106 | events-first | 1 |
107 | exacerbation-like | 1 |
108 | exact-defined | 1 |
109 | expectation/placebo | 1 |
110 | extreme-heat | 1 |
111 | few-electron | 1 |
112 | gabapentin.adverse | 1 |
113 | gene-loss | 1 |
114 | glycogen-sparing | 1 |
115 | heat-/cold-related | 1 |
116 | hit-related | 1 |
117 | hole-scavenging | 1 |
118 | hopelessness-specific | 1 |
119 | hot-weather-related | 1 |
120 | hyperaemia-type | 1 |
121 | hyperglycaemia-related | 1 |
122 | implant-site | 1 |
123 | impulsivity-specific | 1 |
124 | is26-mediated | 1 |
125 | ischemia-reperfusion-related | 1 |
126 | isogyric | 1 |
127 | laboratory-adverse | 1 |
128 | late-season | 1 |
129 | later/no | 1 |
130 | left-moving | 1 |
131 | life.adverse | 1 |
132 | lines/sines-mediated | 1 |
133 | luisotropic | 1 |
134 | mace-related | 1 |
135 | macroaspiration | 1 |
136 | meddra-coded | 1 |
137 | membrane-proximal-signalling | 1 |
138 | mgd-mediated | 1 |
139 | micro-evolutionary | 1 |
140 | mid-brunhes | 1 |
141 | myopathy-associated | 1 |
142 | neurodegenerative-related | 1 |
143 | neurological/extrarenal | 1 |
144 | neuropsychniatric | 1 |
145 | neutrino-induced | 1 |
146 | nmd-activating | 1 |
147 | non-aquatic | 1 |
148 | non-hl | 1 |
149 | non-treatment-ascribed | 1 |
150 | nonbronchoconstrictor | 1 |
151 | nontarget-lesion | 1 |
152 | nucleation/annihilation | 1 |
153 | observed-expected | 1 |
154 | once-neutral | 1 |
155 | once-occurring | 1 |
156 | outcomes-vascular | 1 |
157 | pain/fatigue/adverse | 1 |
158 | paleopolyploidization | 1 |
159 | pathoadaption | 1 |
160 | perireceptor | 1 |
161 | physiological-emotional | 1 |
162 | pooled-arm | 1 |
163 | positive-urine | 1 |
164 | post-nonfatal | 1 |
165 | post-vascular | 1 |
166 | power-lifting | 1 |
167 | radiation-pneumonitis | 1 |
168 | rbv-related | 1 |
169 | re-classify | 1 |
170 | reaction/adverse | 1 |
171 | rebook | 1 |
172 | recombination/reassortment | 1 |
173 | right-moving | 1 |
174 | sepsis-inducing | 1 |
175 | side-effects/adverse | 1 |
176 | sleepwalking-like | 1 |
177 | sm-promoted | 1 |
178 | sound-pressure | 1 |
179 | stoechiokinetic | 1 |
180 | syto16+cd45-cd31-cd140b+ | 1 |
181 | thromboembolic/thrombotic | 1 |
182 | thrombotic/embolic | 1 |
183 | thromoembolic | 1 |
184 | time-to-recurrent | 1 |
185 | treatment-adverse | 1 |
186 | trial-qualifying | 1 |
187 | vaccine-adverse | 1 |
188 | vanilloid-related | 1 |
189 | veno-thromboembolic | 1 |
190 | venothromboembolic | 1 |
191 | wet-weather-related | 1 |
192 | ~bullet~adverse | 1 |
1 | ''adverse | 1 |
2 | 'adverse | 12 |
3 | 'remedy | 2 |
4 | 11/1223 | 1 |
5 | 13,308 | 1 |
6 | 16,679 | 1 |
7 | 3/4-related | 1 |
8 | 4,986 | 1 |
9 | 5544 | 1 |
10 | 6.9+/-1.7 | 1 |
11 | 6414 | 1 |
12 | action-contingent | 1 |
13 | administration-related | 3 |
14 | adverge | 1 |
15 | advers | 1 |
16 | adverse | 52,978 |
17 | adverses | 1 |
18 | anaphylactoid-like | 2 |
19 | anti-alf | 2 |
20 | aps-related | 1 |
21 | arteriothrombotic | 8 |
22 | asa-related | 1 |
23 | asynchronic | 1 |
24 | athero-thrombotic | 2 |
25 | axl-dependent | 1 |
26 | bcr-mediated | 1 |
27 | behavioural-pharmacological | 1 |
28 | bleeding/adverse | 2 |
29 | both.adverse | 1 |
30 | bph-defining | 1 |
31 | bradyarrhythmic | 1 |
32 | calamitous | 1 |
33 | calculation.cardiovascular | 1 |
34 | cardiothrombotic | 1 |
35 | cardiovasculars | 1 |
36 | cardioâ-vascular | 1 |
37 | cerebralvascular | 1 |
38 | cerebroischemic | 1 |
39 | cerebrovascular/cardiovascular | 2 |
40 | cerebrovasular | 1 |
41 | ceverbrovascular | 1 |
42 | chd.chd | 1 |
43 | chnpp | 1 |
44 | cholinergically-mediated | 1 |
45 | chronic-inflammatory | 1 |
46 | cisplatin-dependent | 1 |
47 | clinician-documented | 1 |
48 | co-benefit | 1 |
49 | competition-like | 1 |
50 | complications/adverse | 6 |
51 | cononary | 1 |
52 | context/meaning | 1 |
53 | cospeciation | 1 |
54 | cpp-l | 6 |
55 | cross-setting | 1 |
56 | cv/cb | 6 |
57 | cyc=154 | 1 |
58 | deferiprone.adverse | 1 |
59 | deleterius | 1 |
60 | desferrioxamine.adverse | 1 |
61 | disclosable | 1 |
62 | disulfiram-alcohol | 1 |
63 | domino-type | 1 |
64 | dopaminergic/stimulant | 1 |
65 | drug-adverse | 2 |
66 | effect.adverse | 1 |
67 | effects.adverse | 1 |
68 | efficacy-versus-adverse | 1 |
69 | embolic/thrombotic | 2 |
70 | emotion-filled | 2 |
71 | epac-based | 1 |
72 | errors/adverse | 1 |
73 | esophageal-related | 1 |
74 | et-related | 1 |
75 | events-first | 1 |
76 | exacerbation-like | 1 |
77 | exact-defined | 1 |
78 | expectation/placebo | 1 |
79 | extreme-heat | 1 |
80 | few-electron | 1 |
81 | function-modifying | 2 |
82 | gabapentin.adverse | 1 |
83 | gene-loss | 1 |
84 | glycogen-sparing | 1 |
85 | group.adverse | 2 |
86 | groups.adverse | 2 |
87 | heat-/cold-related | 1 |
88 | hit-related | 1 |
89 | hole-scavenging | 1 |
90 | hopelessness-specific | 1 |
91 | hostility-related | 3 |
92 | hot-weather-related | 1 |
93 | hyperaemia-type | 1 |
94 | hyperglycaemia-related | 1 |
95 | ild-like | 2 |
96 | implant-site | 1 |
97 | impulsivity-specific | 1 |
98 | incisional-complication | 2 |
99 | intrasedation | 3 |
100 | iop-related | 3 |
101 | is26-mediated | 1 |
102 | ischemia-reperfusion-related | 1 |
103 | isogyric | 1 |
104 | laboratory-adverse | 1 |
105 | late-season | 1 |
106 | later/no | 1 |
107 | left-moving | 1 |
108 | life.adverse | 1 |
109 | lines/sines-mediated | 1 |
110 | local-site | 2 |
111 | luisotropic | 1 |
112 | mace-related | 1 |
113 | macroaspiration | 1 |
114 | meddra-coded | 1 |
115 | membrane-proximal-signalling | 1 |
116 | meta-analysis.adverse | 2 |
117 | mgd-mediated | 1 |
118 | micro-evolutionary | 1 |
119 | mid-brunhes | 1 |
120 | myopathy-associated | 1 |
121 | neurodegenerative-related | 1 |
122 | neurological/extrarenal | 1 |
123 | neuropsychniatric | 1 |
124 | neutrino-induced | 1 |
125 | nmd-activating | 1 |
126 | non-aids/death | 4 |
127 | non-aquatic | 1 |
128 | non-hl | 1 |
129 | non-treatment-ascribed | 1 |
130 | nonbronchoconstrictor | 1 |
131 | nonsignal | 3 |
132 | nontarget-lesion | 1 |
133 | nucleation/annihilation | 1 |
134 | observed-expected | 1 |
135 | once-neutral | 1 |
136 | once-occurring | 1 |
137 | osteoactive | 2 |
138 | outcomes-vascular | 1 |
139 | pain/fatigue/adverse | 1 |
140 | paleopolyploidization | 1 |
141 | participants.adverse | 2 |
142 | pathoadaption | 1 |
143 | perireceptor | 1 |
144 | physiological-emotional | 1 |
145 | placebo.adverse | 4 |
146 | pooled-arm | 1 |
147 | positive-urine | 1 |
148 | post-nonfatal | 1 |
149 | post-vascular | 1 |
150 | power-lifting | 1 |
151 | pre-gliotic | 2 |
152 | radiation-pneumonitis | 1 |
153 | rbv-related | 1 |
154 | re-classify | 1 |
155 | reaction/adverse | 1 |
156 | rebook | 1 |
157 | recombination/reassortment | 1 |
158 | renal/hypertension | 2 |
159 | right-moving | 1 |
160 | safety/adverse | 2 |
161 | sepsis-inducing | 1 |
162 | side-effects/adverse | 1 |
163 | skeleton-related | 5 |
164 | sleepwalking-like | 1 |
165 | sm-promoted | 1 |
166 | sound-pressure | 1 |
167 | stoechiokinetic | 1 |
168 | stress/life | 2 |
169 | stroke/thromboembolic | 2 |
170 | syto16+cd45-cd31-cd140b+ | 1 |
171 | thromboembolic/thrombotic | 1 |
172 | thrombotic/embolic | 1 |
173 | thrombotic/vascular | 4 |
174 | thrombovascular | 10 |
175 | thromoembolic | 1 |
176 | time-to-cv | 4 |
177 | time-to-recurrent | 1 |
178 | toxic/adverse | 4 |
179 | toxicities/adverse | 2 |
180 | toxicity/adverse | 2 |
181 | treatment-adverse | 1 |
182 | treatment.adverse | 2 |
183 | trial-qualifying | 1 |
184 | untoward | 226 |
185 | vaccine-adverse | 1 |
186 | vanilloid-related | 1 |
187 | veno-thromboembolic | 1 |
188 | venothromboembolic | 1 |
189 | volume-related | 3 |
190 | wet-weather-related | 1 |
191 | years.secondary | 2 |
192 | ~bullet~adverse | 1 |
1 | syto16+cd45-cd31-cd140b+ | 1 |
2 | 11/1223 | 1 |
3 | 6414 | 1 |
4 | 5544 | 1 |
5 | cyc=154 | 1 |
6 | 4,986 | 1 |
7 | 6.9+/-1.7 | 1 |
8 | 13,308 | 1 |
9 | 16,679 | 1 |
10 | cv/cb | 6 |
11 | hopelessness-specific | 1 |
12 | impulsivity-specific | 1 |
13 | thrombotic/embolic | 1 |
14 | veno-thromboembolic | 1 |
15 | stroke/thromboembolic | 2 |
16 | venothromboembolic | 1 |
17 | thromoembolic | 1 |
18 | cerebroischemic | 1 |
19 | bradyarrhythmic | 1 |
20 | asynchronic | 1 |
21 | luisotropic | 1 |
22 | neuropsychniatric | 1 |
23 | isogyric | 1 |
24 | non-aquatic | 1 |
25 | stoechiokinetic | 1 |
26 | athero-thrombotic | 2 |
27 | embolic/thrombotic | 2 |
28 | thromboembolic/thrombotic | 1 |
29 | cardiothrombotic | 1 |
30 | arteriothrombotic | 8 |
31 | pre-gliotic | 2 |
32 | non-treatment-ascribed | 1 |
33 | neutrino-induced | 1 |
34 | meddra-coded | 1 |
35 | emotion-filled | 2 |
36 | exact-defined | 1 |
37 | epac-based | 1 |
38 | myopathy-associated | 1 |
39 | is26-mediated | 1 |
40 | mgd-mediated | 1 |
41 | bcr-mediated | 1 |
42 | lines/sines-mediated | 1 |
43 | cholinergically-mediated | 1 |
44 | 3/4-related | 1 |
45 | hyperglycaemia-related | 1 |
46 | asa-related | 1 |
47 | vanilloid-related | 1 |
48 | heat-/cold-related | 1 |
49 | mace-related | 1 |
50 | volume-related | 3 |
51 | neurodegenerative-related | 1 |
52 | esophageal-related | 1 |
53 | ischemia-reperfusion-related | 1 |
54 | administration-related | 3 |
55 | skeleton-related | 5 |
56 | iop-related | 3 |
57 | wet-weather-related | 1 |
58 | hot-weather-related | 1 |
59 | aps-related | 1 |
60 | et-related | 1 |
61 | hit-related | 1 |
62 | rbv-related | 1 |
63 | hostility-related | 3 |
64 | observed-expected | 1 |
65 | clinician-documented | 1 |
66 | sm-promoted | 1 |
67 | chd.chd | 1 |
68 | untoward | 226 |
69 | stress/life | 2 |
70 | adverge | 1 |
71 | anaphylactoid-like | 2 |
72 | ild-like | 2 |
73 | sleepwalking-like | 1 |
74 | exacerbation-like | 1 |
75 | competition-like | 1 |
76 | disclosable | 1 |
77 | positive-urine | 1 |
78 | hyperaemia-type | 1 |
79 | domino-type | 1 |
80 | sound-pressure | 1 |
81 | adverse | 52,978 |
82 | 'adverse | 12 |
83 | ''adverse | 1 |
84 | vaccine-adverse | 1 |
85 | drug-adverse | 2 |
86 | efficacy-versus-adverse | 1 |
87 | treatment-adverse | 1 |
88 | laboratory-adverse | 1 |
89 | life.adverse | 1 |
90 | desferrioxamine.adverse | 1 |
91 | deferiprone.adverse | 1 |
92 | both.adverse | 1 |
93 | gabapentin.adverse | 1 |
94 | placebo.adverse | 4 |
95 | group.adverse | 2 |
96 | meta-analysis.adverse | 2 |
97 | groups.adverse | 2 |
98 | effects.adverse | 1 |
99 | participants.adverse | 2 |
100 | effect.adverse | 1 |
101 | treatment.adverse | 2 |
102 | toxic/adverse | 4 |
103 | pain/fatigue/adverse | 1 |
104 | bleeding/adverse | 2 |
105 | reaction/adverse | 1 |
106 | toxicities/adverse | 2 |
107 | complications/adverse | 6 |
108 | errors/adverse | 1 |
109 | side-effects/adverse | 1 |
110 | safety/adverse | 2 |
111 | toxicity/adverse | 2 |
112 | ~bullet~adverse | 1 |
113 | local-site | 2 |
114 | implant-site | 1 |
115 | osteoactive | 2 |
116 | anti-alf | 2 |
117 | sepsis-inducing | 1 |
118 | hole-scavenging | 1 |
119 | membrane-proximal-signalling | 1 |
120 | context/meaning | 1 |
121 | bph-defining | 1 |
122 | glycogen-sparing | 1 |
123 | once-occurring | 1 |
124 | nmd-activating | 1 |
125 | power-lifting | 1 |
126 | cross-setting | 1 |
127 | left-moving | 1 |
128 | right-moving | 1 |
129 | function-modifying | 2 |
130 | trial-qualifying | 1 |
131 | non-aids/death | 4 |
132 | rebook | 1 |
133 | cpp-l | 6 |
134 | behavioural-pharmacological | 1 |
135 | neurological/extrarenal | 1 |
136 | nonsignal | 3 |
137 | physiological-emotional | 1 |
138 | once-neutral | 1 |
139 | post-nonfatal | 1 |
140 | non-hl | 1 |
141 | disulfiram-alcohol | 1 |
142 | pooled-arm | 1 |
143 | nontarget-lesion | 1 |
144 | renal/hypertension | 2 |
145 | incisional-complication | 2 |
146 | intrasedation | 3 |
147 | cospeciation | 1 |
148 | nucleation/annihilation | 1 |
149 | macroaspiration | 1 |
150 | paleopolyploidization | 1 |
151 | pathoadaption | 1 |
152 | few-electron | 1 |
153 | late-season | 1 |
154 | expectation/placebo | 1 |
155 | later/no | 1 |
156 | chnpp | 1 |
157 | outcomes-vascular | 1 |
158 | post-vascular | 1 |
159 | cardioâ-vascular | 1 |
160 | thrombotic/vascular | 4 |
161 | cerebralvascular | 1 |
162 | thrombovascular | 10 |
163 | calculation.cardiovascular | 1 |
164 | cerebrovascular/cardiovascular | 2 |
165 | ceverbrovascular | 1 |
166 | cerebrovasular | 1 |
167 | nonbronchoconstrictor | 1 |
168 | perireceptor | 1 |
169 | mid-brunhes | 1 |
170 | adverses | 1 |
171 | radiation-pneumonitis | 1 |
172 | cardiovasculars | 1 |
173 | advers | 1 |
174 | gene-loss | 1 |
175 | deleterius | 1 |
176 | calamitous | 1 |
177 | extreme-heat | 1 |
178 | co-benefit | 1 |
179 | dopaminergic/stimulant | 1 |
180 | axl-dependent | 1 |
181 | cisplatin-dependent | 1 |
182 | action-contingent | 1 |
183 | recombination/reassortment | 1 |
184 | time-to-recurrent | 1 |
185 | events-first | 1 |
186 | time-to-cv | 4 |
187 | 'remedy | 2 |
188 | re-classify | 1 |
189 | years.secondary | 2 |
190 | micro-evolutionary | 1 |
191 | cononary | 1 |
192 | chronic-inflammatory | 1 |